Neuronascent has submitted a number of provisional and PCT patent applications for the use of families of structures that promote neurogenesis as therapeutics for neurodegenerative and psychiatric disorders. Claims on three families of neurogenic agents cover use and composition of families which Neuronascent has identified, synthesized and tested in the laboratory and in animal models. Neuronascent's lead preclinical candidates for AD and depression are covered under this patent application. National filings in North America, Europe, and Asia were submitted in March 2008.

Another back-up family for neurodegenerative diseases like AD and Parkinson's disease will enter National filings in December 2009.

Neuronascent has also submitted a provisional patent and PCT covering the isolation and use of adult neural stem cells from Arctic ground squirrels. This product is useful for the development of potentially novel stroke therapies and for sale to researchers.